Efficacy of Oral Eplerenone for the Treatment of Chronic Central Serous

Abstract

Background: Central serous chorioretinopathy is a sight threatening disease characterized by accumulation of serous sub retinal fluid occurs due to serous detachment of neurosensory retina and retinal pigment epithelium.Purpose: To evaluate the efficacy of oral Eplerenone in patients with chronic CSCR. Methods: In a tertiary care hospital, a prospective analysis of all the patients with chronic CSCR treated with oral Eplerenone who had been seen for at least three months were prospectively analyzed in a tertiary care hospital. Changes in CMT as measured by spectral-domain OCT served as the primary outcome. Changes in BCVA as measured by log MAR and the number of patients obtaining full resolution of SRF served as the secondary outcomes.Results: In 25 patients (15M /10F) treated with 25mg and 50mg of oral Eplerenone were included. The mean age of follow up was 21±17.6 wks. Mean CMT decreased from 401±133 to 317±75μm at 6 wks& to 285±68μm at 3 months. Mean height of SRF decreased from 157±113 to 78±89μm at 6 wks& to 51±79μm at 3 months. Complete resolution of SRF was found in 15 pts after 3 months. BCVA (log MAR) improved from 0.2±0.18 to 0.14±0.16 at 6 wks & to 0.07±0.13 in 3 months.
Conclusion: Eplerenone therapy may improve BCVA & decrease CMT and SRF height in pts with chronic CSCR.